We have located links that may give you full text access.
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Current Opinion in Oncology 2018 May
PURPOSE OF REVIEW: Summarizes recent advances in the treatment of metastatic castration-sensitive and castration-resistant prostate cancer.
RECENT FINDINGS: New randomized data suggest a survival advantage to early abiraterone in castration-sensitive metastatic prostate cancer. Prospective and retrospective studies are examining sequencing of existing cytotoxic and androgen-receptor-targeted therapies in both castration-sensitive and castration-resistant disease. Genomic analysis of both circulating tumor cells and circulating tumor nucleic acids is being examined as a potential method for selecting existing therapies and identifying novel therapeutic targets. Finally, immunotherapy combinations are being evaluated in the setting of advanced prostate cancer.
SUMMARY: In this review, we hope to summarize the recent data supporting the use of early abiraterone in castration-sensitive metastatic prostate cancer and discuss how this data might be incorporated with previous trials showing a survival advantage to early docetaxel. We present recent series examining sequencing of approved therapies as well as trials evaluating novel biomarkers and genomic analyses designed to help choose from among approved therapies or evaluate drugs in development. Lastly, we review ongoing trials examining novel immunotherapy combinations in advanced prostate cancer.
RECENT FINDINGS: New randomized data suggest a survival advantage to early abiraterone in castration-sensitive metastatic prostate cancer. Prospective and retrospective studies are examining sequencing of existing cytotoxic and androgen-receptor-targeted therapies in both castration-sensitive and castration-resistant disease. Genomic analysis of both circulating tumor cells and circulating tumor nucleic acids is being examined as a potential method for selecting existing therapies and identifying novel therapeutic targets. Finally, immunotherapy combinations are being evaluated in the setting of advanced prostate cancer.
SUMMARY: In this review, we hope to summarize the recent data supporting the use of early abiraterone in castration-sensitive metastatic prostate cancer and discuss how this data might be incorporated with previous trials showing a survival advantage to early docetaxel. We present recent series examining sequencing of approved therapies as well as trials evaluating novel biomarkers and genomic analyses designed to help choose from among approved therapies or evaluate drugs in development. Lastly, we review ongoing trials examining novel immunotherapy combinations in advanced prostate cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app